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Oral glucocorticoids are widely used to treat exacerbations of asthma and COPD. A role for their use in treating exacerbations in Cystic
Fibrosis (CF) is not proven. We describe the current practice, amongst UK adult CF physicians, of oral glucocorticoid use as an adjuvant to
intravenous (IV) antibiotic treatment during CF pulmonary exacerbation (P EX). The survey also examined whether physicians thought a
randomised controlled trial (RCT) was necessary and their willingness to participate patients in such a trial.
Eighty one percent of physicians replied. All of them used corticosteroids with P EX. Most physicians supported the need for a RCT and
would be willing to enrol consenting patients in the trial.
This survey highlighted the need for a RCT which would examine the role of adjuvant corticosteroids to IV antibiotics in CF P EX.
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The use of glucocorticoids during pulmonary exacerba-
tions to reduce local and systemic inflammation is well
established in asthma [1] and COPD [2]. There are some
similarities between CF and COPD but it is not clear if oral
corticosteroids are useful in the treatment of exacerbations
in CF. Not withstanding the differences between the age of
patients and the predominant antigen in CF and COPD, the
narrowing of airway caliber in both diseases is not
reversible with bronchodilators. Neutrophils are the pre-
dominant inflammatory cells in both conditions. The
precise reasons for pulmonary exacerbations in CF and
COPD are not clear.
A prospective randomised placebo-controlled trial of
oral glucocorticoids, as an adjuvant to conventional treat-
ment, has been shown to increase FEV1, improve quality of⁎ Corresponding author.
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doi:10.1016/j.jcf.2006.12.009life, and to shorten hospital stay, during P EX in COPD [3].
In CF, a small study of oral prednisolone given with IV
antibiotics during a pulmonary exacerbation showed a
trend towards favorable response compared with placebo;
but the results of the comparison did not reach statistical
significance [4]. To date there has been no large trial
investigating whether the addition of short-term oral
corticosteroids to (IV) antibiotics improves the outcome
of P EX in CF.
A Cochrane systematic review examined trials that
investigated the benefits and harm of long-term oral corti-
costeroids. It included 3 RCTs in which 354 CF patients
were investigated [5]. The long-term use of prednisolone
was found to improve FEV1, but was associated with
increased side effects, including cataracts, growth impair-
ment and diabetes [6,7]. Some of these side effects lasted for
a prolonged period of time following cessation of pred-
nisolone [8]. The role of long term inhaled steroids in CF
has now been questioned after recent research found no
evidence of increased P EX after withdrawal of inhaled
corticosteroids [9].ed by Elsevier B.V. All rights reserved.
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found no studies on the addition of prednisolone to IV
treatment during P EX. The reviewers identified the need for
research into the use of short courses of oral corticosteroids,
in conjunction with antibiotics, during P EX. With short
courses of oral glucocorticoids the anticipated side effects
would be minimal.
Conversations with adult physicians in the UK and
Europe indicated that the use of glucocorticoids with
antibiotics during P EX was not uncommon. A formal
survey seeking views on the frequency of use and the attitude
of physicians to the use of oral glucocorticoids during P EX
was undertaken.
The aim of this study was to establish current practices
and attitudes of UKCF physicians regarding the use of
adjuvant glucocorticoid treatment in adult CF patients
requiring IV antibiotics for P EX and to determine the
feasibility of a prospective RCT.
2. Methods
A questionnaire was sent to all adult CF physicians
named on the records of the UK CF Trust. Questions
addressed: 1. Current usage of glucocorticoids during P EX
2. Reasons for not using glucocorticoids during P EX 3.
Attitude towards a potential RCT of short courses of
prednisolone as an adjuvant to IV antibiotics and 4. Interest
in participating in such a trial. (Questionnaire as Appendix).
Responses were mostly multiple choice in nature
indicating level of agreement with statements made. The
investigators were also asked to state whether they cared for
more than or less than 50 CF patients.
3. Results
34 of the 42 physicians contacted (81%) completed and
returned the questionnaire. Of those who completed the
questionnaire, 65% cared for more than 50 adult CF patients.
All of the responders used glucocorticoids with IV
antibiotics in their current practice. 61% of those stated that
they used them very rarely or occasionally, 21% fairly
regularly, and 8% often. Of those who stated reasons for not
using glucocorticoids, 61% stated lack of convincing
literature or lack of efficacy from personal experience and
47% cited potential side effects.
Using Chi Squared analysis, there were no significant
differences in responses from physicians in large (N50 patients)
or small (b50 patients) units. Most responders (88%) agreed
that a large prospective RCT is required and 75%of thesewould
be willing to enter consenting patients into RCT.
4. Discussion
This is the first survey to explore the attitude of large
group adult CF physicians towards the use of glucocorticoids
during P EX. The survey showed that all UK CF physicianscaring for adult patients are using them to a variable extent as
an adjuvant to IV antibiotics.
The rationale for the use of prednisolone in CF P EX is
probably the assumption that there is an exuberant
inflammation during exacerbations which might be usefully
managed with the addition of glucocorticoids. Another
reason may be that physicians have been extrapolating the
published benefit of prednisolone in asthma and COPD
exacerbations to P EX in CF. The survey did not explore the
dose and the duration of treatment amongst responding
physicians. Unlike long term use of prednisolone, the short
duration of the course of prednisolone as given during P EX
is not likely to result in major side effects.
Some strong views from physicians for and against the
use of glucocorticoids have been expressed in the com-
ment sections of the survey. However, the majority of adult
CF physicians in the UK (nearly 9 out of 10) agreed with
the recommendation of the Cochrane Review that a pro-
spective RCT of glucocorticoid use as an adjuvant to IV
antibiotics during P EX is required. A large proportion of
these would be willing to participate in entering consenting
patients.
This survey calls for an adequately powered prospective,
multi-centre, parallel, randomised, double blind, placebo
controlled trial to investigate the addition of oral predniso-
lone during severe CF P EX requiring IV antibiotics. With
the level of interest expressed during this survey, a sufficient
number of adult UK CF patients would be expected to be
recruited and the trial could feasibly be undertaken. A
proposal of RCT has now being submitted to a national
funding body in the UK.
Appendix A. The questionnaire and responses
QUESTION 1: Have you ever used glucocorticoids with
IV antibiotics in the management of acute CF P EX?Never 0/34 (0%)
Very rarely 7/34 (21%)
Occasionally, in severe exacerbations 17/34 (50%)
Fairly regularly 7/34 (21%)
Often 3/34 (8%)QUESTION 2: If you do not use glucocorticoids during P
EX, please state your reasons (you may circle more than 1
option).Lack of efficacy from personal experience 8/34 (26%)
No convincing literature 12/34 (35%)
Potential bone side effects 8/34 (26%)
Unmasking CF related diabetes 7/34 (21%)
I do not favour using glucocorticoids in patients with
infected lungs1/34 (3%)QUESTION 3: The authors of small studies and a
Cochrane review have advocated that a large prospective
RCT on the use of glucocorticoids as an adjuvant to IV
antibiotics is required. What are your views?
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Agree 20/34 (58.8%)
Would be of moderate interest 7/34 (20.5%)
Do not agree 3/34 (8.8%)
Strongly disagree 1/34 (2.9%)QUESTION 4: Would you be interested in entering
consenting patients into a potential RCT?Yes 20/34 (58.8%)
Yes, but I do not have the infrastructure or time at present 5/34 (14.7%)
I have many trials ongoing but willing to consider 5/34 (14.7%)
I have too many trials ongoing currently 1/34 (2.9%)
I am not interested 3/34 (8.8%)References
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